A Predictive Model for Neutropenia Associated with Cancer Chemotherapy
- 1 July 2000
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 20 (7P2) , 104S-111S
- https://doi.org/10.1592/phco.20.10.104s.35232
Abstract
Studies of primary prophylaxis of febrile neutropenia (FN) with recombinant human granulocyte colony‐stimulating factor (rHu‐G‐CSF, filgrastim) administered to all patients starting their initial cou...Keywords
This publication has 17 references indexed in Scilit:
- The economics of febrile neutropenia: implications for the use of colony-stimulating factorsEuropean Journal Of Cancer, 1998
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Economie impact of granulopoiesis stimulating agents on the management of febrile neutropeniaCurrent Opinion in Oncology, 1998
- Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.Journal of Clinical Oncology, 1996
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapyEuropean Journal Of Cancer, 1993
- Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer ChemotherapyJNCI Journal of the National Cancer Institute, 1993
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal Of Cancer, 1993
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- Hematopoietic Growth FactorsNew England Journal of Medicine, 1989